Menu
ETF
Annual · values202520242023202220212020201920182017201620152014
Operating Cash Flow-7.01 M USD-2.97 M USD-4.76 M USD-6.60 M USD-6.03 M USD-4.78 M USD1.37 M USD-652971 USD-181270 USD-323900 USD-151622 USD-19401 USD
Depreciation & Amortization677364 USD919603 USD200894 USD77301 USD27760 USD11917 USD10788 USD5190 USD2810 USD1878 USD5633 USD10531 USD
Stock-Based Compensation162920 USD1.62 M USD1.54 M USD1.14 M USD69787 USD0 USD
Capital Expenditures43412 USD183703 USD444722 USD10785 USD415710 USD49261 USD64839 USD19400 USD0 USD15700 USD0 USD
Cash Flow from Investing-2.75 M USD363895 USD-2.49 M USD-81217 USD-2.15 M USD-187254 USD-114706 USD-19400 USD0 USD-15700 USD0 USD
Cash Flow from Financing11.10 M USD3.12 M USD7.39 M USD1.09 M USD3.77 M USD13.82 M USD-229465 USD858855 USD54625 USD0 USD625000 USD20000 USD
Dividends Paid
Stock Buybacks
Free Cash Flow-7.06 M USD-3.16 M USD-5.20 M USD-6.61 M USD-6.45 M USD-4.82 M USD1.31 M USD-672371 USD-181270 USD-339600 USD-151622 USD

INVO Fertility, Inc. is a healthcare services company focused on the fertility market, providing assisted reproductive technology care through innovative clinic operations and medical devices. It operates fertility clinics, including branded INVO Centers dedicated primarily to the intravaginal culture procedure enabled by its proprietary INVOcell device, as well as traditional in vitro fertilization clinics. The INVOcell is a medical device that facilitates fertilization and early embryo development in vivo within the woman's body, offering an alternative to conventional lab-based methods. The company also sells and distributes the INVOcell device to third-party fertility clinics. Its services encompass a range of reproductive options such as IVF, intravaginal culture, intrauterine insemination, fertility preservation, and advanced diagnostic testing. INVO Fertility, Inc. maintains a network of operational clinics in the United States and pursues acquisitions to expand its platform. Founded in 2007 and headquartered in Sarasota, Florida, it plays a role in making fertility treatments more accessible in the healthcare sector.